WO2026118186 - METHOD FOR PRODUCING ANTI-CD38 ANTIBODY
National phase entry is expected:
Publication Number
WO/2026/118186
Publication Date
11.06.2026
International Application No.
PCT/CN2025/074774
International Filing Date
24.01.2025
Title **
[English]
METHOD FOR PRODUCING ANTI-CD38 ANTIBODY
[French]
PROCÉDÉ DE PRODUCTION D'UN ANTICORPS ANTI-CD38
[Chinese]
用于生产抗CD38抗体的方法
Applicants **
QILU PHARMACEUTICAL CO., LTD.
Inventors
FU, Maohong
ZHANG, Jianjun
AN, Zhenming
SUN, Lixia
ZHENG, Huanlan
SHI, Qinghua
DONG, Bei
ZHU, Shibo
Priority Data
202411782739.2
05.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1865 | |
| EPO | Filing, Examination, Granting | 14132 | |
| Japan | Filing, Examination, Granting | 2309 | |
| South Korea | Filing, Examination, Granting | 2469 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
25,515
Contact Us
Abstract[English]
Provided in the present invention are a method for controlling the concentration of Mn ions during the preparation of an anti-CD38 antibody so as to improve the content of G1F and G0F oligosaccharide modifications of the antibody, and a method for formulating the antibody into a pharmaceutical product.[French]
La présente invention concerne un procédé de contrôle de la concentration en ions Mn lors de la préparation d'un anticorps anti-CD38 afin d'améliorer la teneur en modifications oligosaccharidiques G1F et G0F de l'anticorps, ainsi qu'un procédé de formulation de l'anticorps en un produit pharmaceutique.[Chinese]
本发明提供了一种在抗CD38抗体制备期间控制Mn离子浓度从而改善抗体G1F、G0F低聚糖修饰含量的方法，以及将所述抗体配制为药物产品的方法。